-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2044 Clonal Expansion and Differentiation of Stem-like Memory T Cells to Tissue-Resident Memory T Cells Perpetuates Pathogenesis of Chronic Graft-Versus-Host Disease

Program: Oral and Poster Abstracts
Session: 701. Experimental Transplantation: Basic and Translational: Poster I
Hematology Disease Topics & Pathways:
Research, Translational Research, immunology, Biological Processes, pathogenesis
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Xiaohui Kong, PhD1,2*, Bixin Wang, MD, PhD1,2*, Xiwei Wu, MD, PhD3*, Hyejin Cho3*, Moqian Zheng1,2*, Yuankun Zhang1,2*, Shanshan Tang, PhD1,2*, Qinjian Li1,4*, Ubaydah Nasri1*, Alyssa Wu1*, Hanjun Qin3*, Raju Pillai, MD5*, Ryotaro Nakamura, MD2, Paul J. Martin, MD6, Yuanzhong Chen, MD7* and Defu Zeng, MD1,2

1Department of Immunology and Theranostics, Arthur Riggs Institute of Diabetes and Metabolism Research, Beckman Research Institute of City of Hope, Duarte, CA
2Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Comprehensive Cancer Center, Duarte, CA
3Department of Integrative Genomics Core, Beckman Research Institute of City of Hope, Duarte, CA
4Army medical University affiliated Xinqiao Hospital, Chongqing, China
5Department of Pathology, City of Hope National Comprehensive Cancer Center, Duarte, CA
6Fred Hutchinson Cancer Center, Seattle, WA
7Fujian Medical University Center of Translational Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China

We and others have shown that tissue-resident memory CD4+ T cells play a critical role in maintaining chronic GVHD pathogenesis. However, the cellular and molecular mechanisms remain largely unknown. Ly108 and (TCF1) expression have been shown to reflect the stemness of memory CD8+ T cells. In the current studies, using the markers Ly108 (TCF1) and CD69, we identified four subsets of memory CD4+ T (Tm) cells in the GVHD target tissues, including Ly108+ CD69- and Ly108+CD69+ stem-like Tm cells, as well as Ly108- CD69- and Ly108- CD69+ differentiated Tm cells. Compared to other Tm subsets, the Ly108- CD69+ subset expressed the highest levels of IFN-γ and GM-CSF without upregulating anergy/exhaustion markers, indicating that they represent a terminally differentiated, tissue resident, pathogenic CD4+ memory T (Trm) subset. The Ly108+ Tm subsets showed self-renewal capacity and differentiation into Ly108- Tm subsets, as demonstrated by adoptive transfer experiments. Using single-cell RNA sequencing (scRNA-seq) in conjunction with scTCR-seq analysis, we observed that Ly108+CD69- Tm subset was clonally related to the expanded Ly108- CD69- and Ly108- CD69+ Tm subsets, suggesting a clonal expansion and differentiation of Ly108+ CD69- stem-like memory T (Tsm) cells. In addition, we found that IFN-γ primed donor-type antigen-presenting cells (APCs) play an essential role in optimizing the transition from CD4+ Tsm cells to CD4+ Trm cells in STAT3- and BCL6-dependent manner, as indicated by ATAC-Seq analysis. Our results have elucidated a novel pathway of clonal expansion and differentiation of Tsm cells to Trm cells in the GVHD target tissues. These observations provide cellular and molecular mechanisms that explain how chronic GVHD is perpetuated by memory T cells in local tissues.

XK and BW contributed equally.

Disclosures: Nasri: Crinetics Pharmaceuticals: Current Employment. Nakamura: Leukemia & Lymphoma Society: Other: grant reviewer; BMT CTN Steering Committee: Membership on an entity's Board of Directors or advisory committees; Miyarisan: Research Funding; International Consortium: Other: consortium chair; NCTN Lymphoma Steering Committee: Membership on an entity's Board of Directors or advisory committees; Mt. Sinai: Other: Acute GVHD; NCCN: Other: guideline panel for HCT; Napajen: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: research collaboration; Omeros: Consultancy; Sanofi: Consultancy; Blue Bird: Consultancy.

*signifies non-member of ASH